Market Size (2021)
2021
—
Vertical: HealthcareBase Year: 202012 Sections
Market Size (2021)
2021
—
Projected (2027)
2027
—
CAGR (2021–2027)
N/A
Key Players
114+
This report covers Diabetes Drugs Market with forecasts from 2021 to 2027. 114 key companies are profiled.
Diabetes Drugs Market is a key focus area for market intelligence and strategic research.
Historical performance and future projections (2020–2030, USD Billion)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansAnalysis of Diabetes Drugs Market from 2021 to 2027. Covers Americas, Asia Pacific, Europe, Middle East and Africa.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThe research starts with the extensive procurement process of data/information and statistics from company annual reports, government websites, statistics agencies, and paid databases. This information creates a base for the study. The information also helps to define the scope and to narrow down the area for study for the market. This raw information is processed and analyzed to extract crisp data points which currently affect or are likely to affect the industry during the forecast period. After analyzing the information, a proprietary statistical tool is used for market estimation and forecast, which generates the quantitative figures/sizes of the market/sub-segments in the current scenario as well as for the forecast period.
After estimating the market sizes and estimates, the numbers are verified with industry participants and key opinion leaders. The wide network of industry participants add value to the research and verify the numbers and estimates provided in the study. At the last stage of the research process, a final report is prepared, which is then published on different websites as well as distributed through various channels. The below figure contains the different stages of the research process to produce the report.
Data mining is an extensive part of our research process. It involves the procurement of market data and related information from different verified and credible sources. This step helps to obtain raw information about the components of the industry and their source, the monetary process for different end uses, the pool of market participants, and the nature of the industry and scope of the study. The data mining stage comprises both primary and secondary sources of information.
In the secondary research process, various sources are used to identify and gather industry trends and information for the research process. We at MRFR have access to some of the most diversified and extensive paid databases, which give us the most accurate data/ information on markets sizes, components, and pricing. Mentioned below is a detailed list of Sources that have been used for this study. Please note that this list is not limited to the names as mentioned; we also access other data Sources depending on the need.
In the primary research process, in-depth primary interviews are conducted with the CXOs to understand the market share, customer base, pricing strategies, channel partners, and other necessary information. Besides, in-depth primary interviews are conducted with the CXOs of vendors, channel partners, and others to validate the supply-side information. In addition, various key industry participants from both the supply and demand side are interviewed to obtain qualitative and quantitative information on the market. In-depth interviews with key primary respondents, including industry professionals, subject matter experts (SMEs), industry consultants, and C-level executives of major companies, are conducted to obtain critical qualitative and quantitative information pertaining to the market, as well as to assess the prospects for market growth during the forecast period. Detailed information on these primary respondents is mentioned below.
We at MRFR follow an extensive process for arriving at market estimations, which involves the use of multiple forecasting techniques as mentioned below.
Understanding the market in terms of valuation is a crucial task. This becomes significantly important while investing in and choosing the correct business opportunities. In this regard, we at MRFR undertake two market sizing approaches simultaneously, namely, the top-down and bottom-up approaches. In this step, we assess different data points, numeric attributes, information, and industry trends to arrive at the estimates and forecast values for the coming years. We use different mathematical models to estimate the market sizes of different economies and segments, each of which is further summed up to define the total market.
We at MRFR employ a proprietary statistical tool for market estimations, which helps us to arrive at market size estimates and forecasts for different markets and industries.
In the bottom-up approach, the revenue of key companies and their shares in the market are assessed to deduce the market size. More than 25 key players operating in the Global Diabetes Drugs market market are studied. The segmental revenue of each player is analyzed and the size for the Global Diabetes Drugs market market is extracted from the segmental/product revenue with the help of secondary and primary research. The extracted size for the market is then validated with industry experts and partner consultants. This derived market size contributes to around 65%–70% of the total global market share in terms of revenue for the Global Diabetes Drugs market market. Using the data triangulation method, the overall global market size is estimated.
The overall market size is then used in the top-down procedure to estimate the size of the other sub-markets with the help of percentage splits of the market segments from secondary and primary research. The demand-side analysis is conducted, in which the expenditure of major industry players in each region is studied.
The countries considered in the scope of the Global Diabetes Drugs market market are the US, Canada, Mexico, the UK, Germany, France, Italy, Spain, China, Japan, India, Australia & New Zealand, South Africa, Egypt, Nigeria, Saudi Arabia, Qatar, the UAE, Bahrain, Kuwait, and Oman, Brazil, Argentina, Chile, and others. However, the number of countries varies according to the market. The figure below depicts the process of market estimation using independent tools employed by our analysts to arrive at the sizing of the market.
As a part of the market engineering, the both top-down and bottom-up approaches are utilized along with data triangulation models to derive and verify the market sizes and forecast over the coming years.
After arriving at the overall market sizes, the total market is divided into several segments and sub-segments. Again, the market breakdown and data triangulation procedures are implemented, wherever applicable, to complete the overall market engineering process and gather the exact statistics for all segments and sub-segments. The data is triangulated by studying various factors and trends from the demand and supply sides. Along with this, the market size is validated using the top-down and bottom-up approaches.
Validation is the most important stage of the report making process. Validation via an intricately designed feedback process helps us finalize the sizing estimates and forecast for the final collation. Extensive primary research is performed to verify the information. This includes telephonic and personal interviews, e-mails, feedback forms, questionnaires, and polling options/answers with a group of relevant industry participants. Validation helps to duly check the authenticity of the key industry trends, market dynamics, company market share, different business models, and conclusions.
Base Year
2020
Historical Period
2021 – 2020
Forecast Period
2020 – 2027
Primary Interviews
150+
Historical data (2021–2020) and forecast period (2020–2027)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
See plans for professionals or small and medium businesses.

Analytical insights on Diabetes Drugs Market covering market dynamics, competitive landscape, and strategic outlook.
Diabetes Drugs Market represents a significant market opportunity with multiple growth drivers across regions and segments.
The Diabetes Drugs Market market encompasses 4 key regions and multiple market segments, with the study period spanning 2021 to 2027.
The market is segmented across multiple dimensions, with detailed breakdowns available by component, region, and application type to support strategic planning and investment decisions.
This report profiles 114 key companies operating in the Diabetes Drugs Market market, covering market positioning, product portfolios, and recent developments.
Leading players include Ely Lilly and Company, Novo Nordisk A/S , Asterazenca, Biocon, Novartis AG, and 109 others.
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Profiles of 114 companies operating in the Diabetes Drugs Market market, including revenue, employee count, and market positioning where available.
Showing 114 of 114 companies
Biocon
Company Headquarters: Karnataka, India Founded: 1978 Workforce: ~16,545 Company Working: Biocon manufactures and sells generic active pharmaceutical ingredients (APIs). It also provides a variety of branded formulations, complex biologics, and biosimilars like monoclonal antibodies (MAbs), rh-Insulin, and insulin analogues in addition to several active pharmaceutical ingredients (APIs). Additionally, the company provides contract manufacturing, medicine licensing, research, development, and the production of both small and large molecules to pharmaceutical and biotechnology organizations all over the world. In order to develop solutions that meet the various needs of patients around the world, Biocon has invested in cutting-edge technology, major research collaborations, and global manufacturing scale over the years. As an emerging international company, Biocon is meeting patients' needs in more than 100 nations with unique products. It has a production unit and an R&D facility at BioXcell in Malaysia. Furthermore, it has operations in the UK, Ireland, the US, Switzerland, Dubai, and Malaysia.
Pfizer Inc.
Company Headquarters: New York, US Founded: 1849 Workforce: ~83,000 Company Working: Pfizer Inc. (Pfizer) is a leading research-based biopharmaceutical company that applies science and resources to provide innovative treatments that extend and significantly improve lives. Pfizer discovers, develops, manufactures, and sells healthcare products worldwide. It operates through two segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs), and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, clinics, government agencies, and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. Furthermore, the company supplies its products in North America, South America, Asia-Pacific, Australia, Europe, Africa, and the Middle East.
Takeda Pharmaceutical Company Limited
Company Headquarters: Japan Founded: 1925 Workforce: ~ 47,347 Company Working: Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs, and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases, and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The Company is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.
Novo Nordisk A/S
Company Headquarters: Bagsværd, Denmark Founded: 1923 Workforce: ~43,258 Company Working: Novo Nordisk A/S (Novo Nordisk) is a Danish pharmaceutical company that discovers, manufactures, and commercializes pharmaceutical products. The company’s operating segments are diabetes, hemophilia, growth disorders, obesity, and other biopharmaceuticals. The company has research and development centers in China, India, Denmark, the UK, and the US. It has a strong clinical pipeline of drugs for conditions such as Type 1 diabetes, Type 2 diabetes, obesity, atherosclerosis, and hemophilia and growth disorders. The company operates in 79 countries and markets its products in more than 170 countries.
Amgen Inc.
Company Overview Company Headquarters: California, US Founded: 1980 Workforce: 20,000+ Company Working: Amgen Inc. (Amgen), a well-known biopharmaceutical company, was founded in 1860. The company focuses on discovering, developing, manufacturing, and delivering innovative human therapeutic products. It uses tools such as advanced human genetics to unravel the intricacies of diseases and understand the fundamentals of human biology. It serves its products in major therapeutic areas such as oncology, cardiovascular disease, inflammation, bone health, nephrology, and neuroscience. Amgen operates through one business segment, namely, human therapeutics. It focuses on areas that have high unmet medical needs and leverages its expertise to develop solutions for improving health outcomes and efficiently improve people's lives. It has become one of the leading independent biotechnology companies in the world.
SANOFI
Sanofi is a UK-based global life sciences company which was incorporated in the year 2004. Sanofi is headquartered in Paris having the employee strength of more than 110,000 spread in more than 100 countries and have industrial sites in more than 40 countries. The company is committed to improve the access to healthcare and support the people to whom it serves throughout the continuum of care. Further, the company has its offerings into healthcare solutions, human vaccines, rare diseases, multiple sclerosis, oncology, immunology, infectious diseases, diabetes and cardiovascular solutions, and consumer healthcare. Sanofi CEPiA is a subsidiary business unit of Sanofi that produces articaine hydrochloride in API form. It is a market leader in producing articaine hydrochloride. The company manufactures articaine hydrochloride in its high capacity FDA approved workshop. Sanofi’s Ankleshwar production plant has an export sales of Rs. 54,900 lakhs that is around 27% of their total sales in India in 2015 . Their healthcare solutions are available in more than 170 countries across the world and now Sanofi is focussing on increasing its presence in emerging countries. Their industrial network, know-how and employees deliver a wide range of health solutions to millions of individuals with high quality and safety. Some of the top competitors of Sanofi are Pfizer Inc., Merck & Co., Inc. GlaxoSmithKline Plc., Septodont, Dentsply Sirona, and Pierrel S.p.A., among others.
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Diabetes Drugs Market